GlassScriptPhysician profile
Olivia Lee Johnson
NPI 1649969460
$2,062.83
in general payments reported to CMS, 2019-2025
28 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $61.15 · 2024: $662 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $230.71 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Boston Scientific Corporation | $181.79 | 2023-2025 | Cds Broad Portfolio Offering, Watchman Flx |
| Ucb, INC. | $167.08 | 2024-2025 | Nayzilam, Briviact |
| Bayer Healthcare Pharmaceuticals INC. | $148.39 | 2024-2025 | |
| Abbvie INC. | $147.01 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $139.27 | 2024-2025 | Fanapt, Ponvory |
| Novo Nordisk INC | $121.94 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $101.44 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $86.53 | 2025 | Yupelri |
| Exact Sciences Corporation | $69.51 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Smith+Nephew, INC. | $68.80 | 2025 | Grafix Pl |
| Sumitomo Pharma America, INC. | $61.11 | 2025 | Gemtesa |
| Mylan Specialty L.P. | $59.30 | 2023-2024 | Yupelri |
| Amgen INC. | $58.21 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Eisai INC. | $52.54 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $46.54 | 2024-2025 | Nuplazid |
| Dexcom, INC. | $44.70 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.25 | 2025 | Rexulti |
| Mannkind Corporation | $37.09 | 2025 | |
| Abiomed | $31.11 | 2025 | |
| Alexion Pharmaceuticals, INC. | $26.17 | 2025 | Ultomiris |
| Paratek Pharmaceuticals, INC. | $25.66 | 2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $22.11 | 2024 | |
| Daiichi Sankyo INC. | $19.95 | 2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $19.94 | 2024 | Voquezna |
| Pfizer INC. | $19.43 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.94 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.